Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update

Key Points

• Y-mAbs Therapeutics experienced a significant decrease in short interest of 25.6% in August, with a total of 1,660,000 shares shorted.
• Equities analysts have generally downgraded Y-mAbs, with a consensus rating of "Reduce" and a price target averaging $9.62.
• The company reported a loss of $0.07 per share for the last quarter, exceeding analyst expectations while generating revenue of $19.52 million.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 15th, there was short interest totaling 1,660,000 shares, adecreaseof25.6% from the July 31st total of 2,230,000 shares. Approximately4.8% of the shares of the company are short sold. Based on an average trading volume of 763,700 shares, the short-interest ratio is currently 2.2 days. Based on an average trading volume of 763,700 shares, the short-interest ratio is currently 2.2 days. Approximately4.8% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a "neutral" rating and issued a $8.60 price target (down from $11.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, August 6th. Jones Trading cut Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Oppenheimer downgraded shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 5th. Truist Financial set a $8.60 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Finally, Brookline Capital Management lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Eight analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of "Reduce" and a consensus price target of $9.62.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $8.58 on Monday. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11. The company has a market capitalization of $389.88 million, a P/E ratio of -17.16 and a beta of 0.53. The firm's 50 day simple moving average is $6.42 and its 200 day simple moving average is $5.27.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. The firm had revenue of $19.52 million for the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. On average, equities analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC lifted its stake in Y-mAbs Therapeutics by 13.1% during the first quarter. Acorn Capital Advisors LLC now owns 3,235,387 shares of the company's stock worth $14,333,000 after purchasing an additional 373,562 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Y-mAbs Therapeutics during the 2nd quarter valued at about $1,587,000. Infinitum Asset Management LLC bought a new stake in Y-mAbs Therapeutics in the 4th quarter worth approximately $1,218,000. Stonepine Capital Management LLC lifted its position in Y-mAbs Therapeutics by 117.5% in the 2nd quarter. Stonepine Capital Management LLC now owns 285,300 shares of the company's stock worth $1,287,000 after buying an additional 154,140 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP boosted its stake in Y-mAbs Therapeutics by 3.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock worth $33,171,000 after buying an additional 150,000 shares in the last quarter. Institutional investors own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.